Market and Product Forecasts: Schizophrenia – The calm after the patent storm

• Publication date: July 2012
• Report size: 47 pages

Coming off the end of a large patent cliff, the schizophrenia market is estimated to be worth $5.2bn in the seven major markets in 2012 (the US, Japan, France, Germany, Italy, Spain, and the UK). Ongoing US price increases and atypical antipsychotic depots will stabilize the market in the medium term, while the fate of novel oral drugs will govern the future direction of the schizophrenia market....

Coming off the end of a large patent cliff, the schizophrenia market is estimated to be worth $5.2bn in the seven major markets in 2012 (the US, Japan, France, Germany, Italy, Spain, and the UK). Ongoing US price increases and atypical antipsychotic depots will stabilize the market in the medium term, while the fate of novel oral drugs will govern the future direction of the schizophrenia market.Access Datamonitor’s patient-based schizophrenia market forecast in the seven major markets, with transparent methodology and clear assumptions.Evaluate a highly granular forecast with sales value and volume projections to 2021 at the country, class, product, and line of therapy levels.Understand schizophrenia market dynamics and which factors will lead to commercial success.Review the products that Datamonitor forecasts to launch over the next 10 years, and how each subsequent launch will shape the market.In the aftermath of recent patent expiries, the oral antipsychotic market with remain flat over 2012–15. However, expansion of the antipsychotic depot class will help the overall schizophrenia market to return to growth, with ongoing uptake of Invega Sustenna and the expected launches of Abilify depot, ALKS 7090, and Fanapt depot.Abilify is the current highest-selling schizophrenia drug, but with Bristol-Myers Squibb and Otsuka due to lose exclusivity for Abilify from Q4 2014, the Abilify depot will assume the position of market leader. As well as competing with established antipsychotic depots, Abilify depot will benefit from Otsuka’s strong Abilify prescriber base.RG1678 will emerge as the most successful of the late-stage oral pipeline. Whereas the majority of its competitors are relatively undifferentiated from currently available products, RG1678 is unique in that it is first-in-class and will have a well-defined therapeutic role, bypassing competition with the fiercely competitive atypical class.How has the schizophrenia market been affected by the influx of generic atypicals?What will the overall schizophrenia market dynamics be over the next 10 years?How will sales of the major drug classes in schizophrenia evolve during the forecast period?What degree of commercial success does Datamonitor forecast for key pipeline drugs?Which of the seven major markets provides the greatest opportunity for growth?

Pathology Industry in the United Kingdom

Autoimmune Disease in United Kingdom

United Kingdom Schizophrenia, Total, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Schizophrenia, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Schizophrenia, 5-14 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Schizophrenia, 0-4 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Schizophrenia, 60-69 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

Pathology in United Kingdom

United Kingdom Respiratory Diseases, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Post-traumatic Stress Disorder, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Peptic Ulcer Disease, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Respiratory Infections, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Protein-energy Malnutrition, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom